Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients
NCT04552288Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2020
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benralizumab in eosinophilic dermatoses, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Percent Reduction in CTCAE Grade 2/3 Eosinophil-related Cutaneous Adverse Events at 4 weeks. Started Sep 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic dermatoses
Beyond the preview
Go deeper on NCT04552288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552288.